Covista Inc. (CVSA) Stock Price & How to Invest

Covista Inc. is the largest healthcare educator in the United States by enrollment, running five accredited institutions across three reporting segments. Chamberlain University is the nursing school and the biggest single revenue line. Walden University is the online graduate institution, weighted toward master's and doctoral programs in nursing, health, education and social work. The Medical and Veterinary segment holds American University of the Caribbean School of Medicine, Ross University School of Medicine and Ross University School of Veterinary Medicine, with campuses in Barbados, St. Kitts and St. Maarten. Revenue is tuition, and a large share of that tuition is funded by federal Title IV student aid. The company is the former DeVry Education Group, which took the Adtalem name in 2017, sold DeVry University in 2018, and spent the four years after that reshaping around healthcare. It announced the Covista name on 5 February 2026 and the ticker moved from ATGE to CVSA on the NYSE on 24 February 2026.

The investment picture is a steady, high-margin operator whose growth is being tested by a change in student lending rules rather than by demand. Fiscal 2026 (ended 30 June 2026) revenue was ~$1,954 million, up ~9.3%, with adjusted EPS of ~$8.25, up ~23.7%, and GAAP diluted EPS of ~$7.04, landing above the ~$7.95 to ~$8.15 adjusted EPS range management had guided to in the spring. In fiscal Q4 2026 revenue was ~$501 million, up ~9.7%, adjusted EPS was ~$2.09 against a ~$1.89 consensus, adjusted operating margin was ~20.1% and total enrollment was ~99,500, up ~8.4%, with Walden up ~14.0% and Chamberlain up ~1.6%. The balance sheet ended the year with ~$406 million of cash against ~$663 million of debt for net leverage of ~0.5x, after ~$238 million of buybacks and a ~$50 million term loan repayment during the year. There is no dividend. For fiscal 2027 management guided to ~$2,050 million to ~$2,090 million of revenue (~5% to ~7% growth) and ~$8.90 to ~$9.15 of adjusted EPS, a step down in revenue growth that lines up with the elimination of Grad PLUS loans on 1 July 2026, which caps most graduate borrowing at ~$20,500 a year and ~$100,000 lifetime and lands squarely on Walden's core programs.

As of 16 October 2026 CVSA closed at $126.54, up ~21% year to date but down ~14% over one year, for a market value of ~$4.3 billion. Fiscal Q1 2027 results are scheduled for 29 October 2026, with consensus near ~$1.83 of EPS on ~$491 million of revenue.

The dominant risk is federal policy rather than competition. Grad PLUS loans ended for new borrowers on 1 July 2026 and most graduate students are now capped at ~$20,500 a year and ~$100,000 lifetime, which is below the full cost of several Walden doctoral pathways and could slow the segment that has been driving enrollment growth; fiscal 2027 revenue guidance of ~5% to ~7% growth already implies a slowdown, and analysts expect the December 2026 quarter's EPS to be roughly flat to slightly lower year over year. The wider Title IV rules matter too: the 90/10 revenue test, gainful employment metrics and accreditation reviews all apply, and a change to any of them affects the whole revenue base. The company also carries a reputational and litigation history, including a ~$28.5 million class action settlement over Walden's DBA program that received final court approval in October 2024, and consumer advocacy groups have continued to criticize the institutions after the rebrand. Operationally, Chamberlain enrollment growth has been low single digits (~1.6% in fiscal Q4 2026), and the gap between adjusted EPS (~$8.25) and GAAP EPS (~$7.04) for fiscal 2026 is worth checking in the filings. The shares are still down ~14% over one year despite the 2026 rebound, and some research outlets have flagged the stock as one to avoid.

4 analysts publish price targets on CVSA, averaging $159.00 against a $122.97 price as of November 2026, or +29.3%. The published targets run from $140.00 to $175.00, a narrow spread, and the ratings split 3 buy, 1 hold, 0 sell. Over the last six months there has been 1 raise and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CVSA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Covista Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Nursing demand and the Chamberlain pipeline. Chamberlain is the nursing school and the largest segment, with ~39,500 students at the end of fiscal 2026, up ~1.6%. The most optimistic published target, $175.00, assumes this works close to its best case.

The case against. The dominant risk is federal policy rather than competition. The most pessimistic target, $140.00, is roughly what CVSA is worth if this bites instead.

Read the full bull and bear case on CVSA, including what would have to change to break either one. Walnut is not an investment adviser.

No. Covista Inc. (CVSA) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Covista Inc.'s investor relations page or your broker.

• Revenue (FY2026): ~$1.95 billion, up ~9.3%
• Adjusted EPS (FY2026 actual / FY2027 guidance): ~$8.25 / ~$8.90 to ~$9.15
• Adjusted operating margin (Q4 FY2026): ~20.1%
• Net income (TTM, GAAP): ~$267 million (margin ~12.9%)
• Market cap: ~$4.3 billion
• Trailing / forward P/E: ~17x / ~13x
• Total enrollment (end FY2026): ~99,500, up ~8.4%
• Net leverage: ~0.5x

Shares trade near ~$127, up ~21% this year but down ~14% over the past 52 weeks, for an EV/EBITDA multiple around ~11x and roughly ~14x the midpoint of fiscal 2027 adjusted EPS guidance. Adjusted profit continues to run ahead of reported profit, a gap worth checking in the filings. Fiscal Q1 2027 results land on 29 October 2026, and the average analyst price target sits near ~$159.

Other names that sit close to CVSA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CVSA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CVSA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CVSA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Covista is a profitable, cash-generative healthcare education operator on a modest multiple, and the case turns on whether Walden's graduate enrollment holds up under the new federal borrowing limits; guidance for slower fiscal 2027 growth suggests management expects some drag but not a collapse.

Whether CVSA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CVSA a buy or a sell?, and where the stock could go from here in the CVSA stock forecast.

For income investors, whether CVSA pays a dividend and how the payout looks is covered in does CVSA pay a dividend? And to weigh CVSA against a peer, read the full side-by-side comparisons: CVSA vs LOPE and CVSA vs PRDO.